Intra Cellular Therapies | ITCI - Операционный доход



Операционный доход Изменить Дата
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
J&J USD 6.62B 1.03B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 521M 2025-12
Prothena USD -27.21M 12.55M 2025-12
RedHill Biopharma USD -4.22M 1.8M 2024-06
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12